BCNU (Carmustine) and Gliadel (Carmustine Wafers): Revision history

31 March 2024

• curprev 12:5812:58, 31 March 2024‎ Lazy talk contribs‎ 10,040 bytes −14‎ No edit summary

30 March 2024

• curprev 10:0810:08, 30 March 2024‎ Lazy talk contribs‎ 10,054 bytes 0‎ No edit summary

27 March 2024

• curprev 20:1820:18, 27 March 2024‎ Lazy talk contribs‎ 10,054 bytes +4,355‎ No edit summary
• curprev 08:5508:55, 27 March 2024‎ Lazy talk contribs‎ 5,699 bytes +650‎ No edit summary

25 March 2024

• curprev 22:5722:57, 25 March 2024‎ Lazy talk contribs‎ 5,049 bytes +4,472‎ No edit summary

24 March 2024

• curprev 05:1005:10, 24 March 2024‎ Lazy talk contribs‎ 577 bytes +577‎ Created page with "{{TreatmentInfo |drug_name=BCNU and Gliadel Wafers |FDA_approval=Yes |used_for=High-grade gliomas |clinical_trial_phase=Phase III (Europe for Gliadel) |common_side_effects=Low blood counts, pulmonary problems, infection, and seizures for Gliadel |OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months |usefulness_rating=4 |notes=While Gliadel wafers alone offer modest improvement, combining them with the standard..."